EC
PMVP icon

Euclidean Capital’s PMV Pharmaceuticals PMVP Stock Holding History

Euclidean Capital’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.26M Hold
2,627,643
– – 0.83% 6
2025
Q4 		$3.28M Hold
2,627,643
– – 0.89% 6
2025
Q3 		$3.68M Hold
2,627,643
– – 1.55% 6
2025
Q2 		$2.79M Hold
2,627,643
– – 0.91% 5
2025
Q1 		$2.86M Hold
2,627,643
– – 1.08% 5
2024
Q4 		$3.97M Hold
2,627,643
– – 0.54% 6
2024
Q3 		$3.92M Hold
2,627,643
– – 0.43% 7
2024
Q2 		$4.26M Hold
2,627,643
– – 0.53% 6
2024
Q1 		$4.47M Hold
2,627,643
– – 0.57% 10
2023
Q4 		$8.15M Hold
2,627,643
– – 0.92% 9
2023
Q3 		$16.1M Buy
2,627,643
+82,401
+3% +$567K 3.52% 4
2023
Q2 		$15.9M Buy
2,545,242
+208,333
+9% +$1.09M 4.09% 5
2023
Q1 		$11.1M Hold
2,336,909
– – 9.78% 3
2022
Q4 		$20.3M Hold
2,336,909
– – 19.02% 3
2022
Q3 		$27.8M Hold
2,336,909
– – 25.82% 2
2022
Q2 		$33.3M Hold
2,336,909
– – 28.32% 1
2022
Q1 		$48.7M Hold
2,336,909
– – 28.27% 1
2021
Q4 		$54M Sell
2,336,909
-432,904
-16% -$10.5M 30.69% 1
2021
Q3 		$82.5M Sell
2,769,813
-1,138,864
-29% -$36.4M 40.12% 1
2021
Q2 		$134M Sell
3,908,677
-270,739
-6% -$9.04M 43.34% 1
2021
Q1 		$137M Hold
4,179,416
– – 45.99% 1
2020
Q4 		$257M Buy
+4,179,416
New +$164M 54.42% 1

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Euclidean Capital's PMVP Position: Q1 2026 in Review

Euclidean Capital held its PMV Pharmaceuticals (PMVP) position steady in Q1 2026 at 2,627,643 shares worth $3.26M. The position accounts for 0.83% of the portfolio, ranked #6.

Euclidean Capital first reported a position in PMVP in Q4 2020 and has held it in 22 quarters since. The position peaked at $257M in Q4 2020. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • Euclidean Capital held 2,627,643 shares of PMV Pharmaceuticals worth $3.26M as of Q1 2026.
  • Euclidean Capital left its PMV Pharmaceuticals share count unchanged in Q1 2026.
  • PMV Pharmaceuticals made up 0.83% of Euclidean Capital's portfolio in Q1 2026, its #6 holding.
  • Euclidean Capital first reported a position in PMV Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Euclidean Capital's PMV Pharmaceuticals position peaked at $257M in Q4 2020.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Euclidean Capital's 13F filing for Q1 2026, filed 15 May 2026.